MUMPS
MCID: MMP001
MIFTS: 56

Mumps (MUMPS)

Categories: Infectious diseases, Oral diseases, Rare diseases

Aliases & Classifications for Mumps

MalaCards integrated aliases for Mumps:

Name: Mumps 12 73 20 54 42 3 44 15 70 32

Classifications:



External Ids:

Disease Ontology 12 DOID:10264
ICD9CM 34 072
MeSH 44 D009107
NCIt 50 C29888
SNOMED-CT 67 154352008
ICD10 32 B26 B26.8 B26.9
UMLS 70 C0026780

Summaries for Mumps

MedlinePlus : 42 Mumps is an illness caused by the mumps virus. It starts with Fever Headache Muscle aches Tiredness Loss of appetite After that, the salivary glands under the ears or jaw become swollen and tender. The swelling can be on one or both sides of the face. Symptoms last 7 to 10 days. Serious complications are rare. You can catch mumps by being with another person who has it. There is no treatment for mumps, but the measles-mumps-rubella (MMR) vaccine can prevent it. Before the routine vaccination program in the United States, mumps was a common illness in infants, children and young adults. Now it is a rare disease in the U.S. Centers for Disease Control and Prevention

MalaCards based summary : Mumps is related to subacute thyroiditis and acute disseminated encephalomyelitis, and has symptoms including fever and pruritus. An important gene associated with Mumps is STAT2 (Signal Transducer And Activator Of Transcription 2), and among its related pathways/superpathways are Innate Immune System and Viral mRNA Translation. The drugs Antibodies and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include skin, salivary gland and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A viral infectious disease that results in inflammation located in salivary gland, has material basis in Mumps rubulavirus, which is transmitted by droplet spread of saliva or mucus from the mouth, nose, or throat of an infected person, or transmitted by contaminated fomites. The infection has symptom fever, has symptom headache, has symptom muscle aches, has symptom tiredness, has symptom loss of appetite, has symptom swollen and tender salivary glands under the ears or jaw on one or both sides of the face.

CDC : 3 Mumps is a contagious disease that is caused by a virus. It typically starts with a few days of fever, headache, muscle aches, tiredness, and loss of appetite. Then most people will have swelling of their salivary glands. This is what causes the puffy cheeks and a tender, swollen jaw.

Wikipedia : 73 Mumps is a viral disease caused by the mumps virus. Initial symptoms are non-specific and include fever,... more...

Related Diseases for Mumps

Diseases in the Mumps family:

Congenital Mumps

Diseases related to Mumps via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 837)
# Related Disease Score Top Affiliating Genes
1 subacute thyroiditis 31.8 TNF IL6 IL1B
2 acute disseminated encephalomyelitis 31.7 IL1B IL10 IFNB1
3 acute pancreatitis 31.5 TNF IL6 IL1B IL10
4 meningoencephalitis 31.2 TNF IL6 IL10
5 aseptic meningitis 31.0 TNF IL1B IL10 IFNG
6 orchitis 31.0 TNF IL6 IL2 IL1B IL10
7 pertussis 30.9 TNF IL6 IL1B IL10
8 purpura 30.7 TNF IL6 IL10 IFNG
9 parainfluenza virus type 3 30.7 IFNB1 IFNA1
10 rubella 30.7 TNF TLR3 IL6 IL2 IL1B IL10
11 newcastle disease 30.6 TNF TLR3 IFNB1 IFNA1 EIF2AK2
12 transverse myelitis 30.5 TNF IL6 IL10
13 chickenpox 30.5 TNF STAT1 IL6 IL2 IL10 IFNG
14 meningitis 30.5 TNF IL6 IL2 IL1B IL10 IFNG
15 encephalitis 30.5 TNF TLR3 IL6 IL1B IL10 IFNB1
16 hepatitis 30.4 TNF IFNG IFNAR2 IFNA1 EIF2AK2
17 optic neuritis 30.4 TNF IL6 IL1B IL10
18 poliomyelitis 30.3 TNF TLR3 IL10 IFNG IFNA1
19 tetanus 30.3 TNF IL6 IL2 IL1B IL10 IFNG
20 iritis 30.3 TNF IL6 IL10
21 measles 30.3 TNF TLR3 STAT2 STAT1 IL6 IL2
22 yellow fever 30.3 STAT1 IL6 IL1B IFNB1
23 acute transverse myelitis 30.3 IL6 IL10
24 myelitis 30.2 TNFRSF1A TNF IL6 IL10 IFNB1 HLA-DPB1
25 herpes simplex 30.2 TLR3 STAT2 STAT1 IFNB1 IFNA1 EIF2AK2
26 keratitis, hereditary 30.2 TNF IL6 IL1B IL10
27 neuritis 30.2 TNF IL6 IL1B IL10 IFNG
28 arthropathy 30.1 TNF IL6 IL1B IFNG
29 chronic graft versus host disease 30.1 IL10 IFNG
30 syphilis 30.1 TNF IL6 IFNG
31 food allergy 30.1 TNF IL10 IFNG
32 rabies 30.1 TLR3 STAT2 STAT1 IFNA1
33 allergic disease 30.0 TNF IL6 IL2 IL1B IL10 IFNG
34 covid-19 30.0 STAT1 IL6 IL1B IFNB1 IFNA1
35 exanthem 30.0 TNF IL6 IL2 IL1B IL10 IFNG
36 rosacea 30.0 TNF STAT1 IL6
37 respiratory syncytial virus infectious disease 30.0 IRF1 IFNB1
38 glossitis 30.0 TNF IL6 IL1B
39 iridocyclitis 29.9 TNF IL6 IL1B IL10
40 swine influenza 29.9 TNF IFNB1 IFNA1
41 pharyngitis 29.9 TNF IL6 IL1B
42 sarcoidosis 1 29.9 TNF STAT1 IL2 IL1B IFNG
43 pleurisy 29.9 TNF IL2 IFNG
44 pericarditis 29.9 TNFRSF1A TNF IL6 IL1B IFNG
45 spondyloarthropathy 1 29.9 TNFRSF1A TNF IL6
46 neuromyelitis optica 29.8 IL6 IL1B IFNA1 HLA-DPB1
47 myositis 29.8 TNF IL6 IL2 IL1B IFNG IFNA1
48 enterocolitis 29.8 TNF IL6 IL10 CD46
49 venezuelan equine encephalitis 29.8 STAT2 STAT1 IRF1 IFNG IFNB1 IFNA1
50 kawasaki disease 29.8 TNF IL6 IL1B IL10

Graphical network of the top 20 diseases related to Mumps:



Diseases related to Mumps

Symptoms & Phenotypes for Mumps

UMLS symptoms related to Mumps:


fever; pruritus

GenomeRNAi Phenotypes related to Mumps according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 IL10 IL1B RIPK1 STAT1 TNF TNFRSF1A
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 EIF2AK2 IL10 IL1B IL2 RIPK1 STAT1

MGI Mouse Phenotypes related to Mumps:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 EIF2AK2 IFNAR2 IFNB1 IFNG IL10 IL1B
2 immune system MP:0005387 10.34 EIF2AK2 IFNAR2 IFNB1 IFNG IL10 IL1B
3 homeostasis/metabolism MP:0005376 10.33 IFNAR2 IFNB1 IFNG IL10 IL1B IL2
4 cardiovascular system MP:0005385 10.3 CD46 IFNG IL10 IL1B IL2 IL6
5 mortality/aging MP:0010768 10.2 EIF2AK2 IFNAR2 IFNG IL10 IL1B IL2
6 endocrine/exocrine gland MP:0005379 10.19 IFNG IL10 IL2 IL6 IRF1 RIPK1
7 digestive/alimentary MP:0005381 10.11 IFNG IL10 IL2 IL6 RIPK1 STAT1
8 integument MP:0010771 10.06 IFNG IL10 IL1B IL6 IRF1 RIPK1
9 liver/biliary system MP:0005370 9.97 IFNG IL10 IL2 IL6 RIPK1 STAT1
10 neoplasm MP:0002006 9.97 EIF2AK2 IFNAR2 IFNB1 IFNG IL10 IL1B
11 muscle MP:0005369 9.86 IFNG IL10 IL6 IRAK1 STAT1 TLR3
12 respiratory system MP:0005388 9.56 IFNG IL10 IL2 IL6 STAT1 TLR3
13 skeleton MP:0005390 9.32 IFNB1 IFNG IL10 IL1B IL6 IRAK1

Drugs & Therapeutics for Mumps

Drugs for Mumps (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4
2 Immunoglobulins Phase 4
3 Pharmaceutical Solutions Phase 4
4 Immunologic Factors Phase 4
5 Vaccines Phase 4
6
Lactitol Approved, Investigational Phase 3 585-86-4 157355
7
Podophyllin Approved Phase 3 9000-55-9
8
Petrolatum Approved, Investigational Phase 3 8009-03-8
9 Immunoglobulins, Intravenous Phase 3
10 Hemagglutinins Phase 3
11 Somatomedin B Phase 3
12 taxane Phase 3
13 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
14 insulin Phase 3
15 Insulin, Globin Zinc Phase 3
16 Dermatologic Agents Phase 3
17 Keratolytic Agents Phase 3
18
BCG vaccine Approved, Investigational
19
Acetylcholine Approved, Investigational 51-84-3 187
20
Lidocaine Approved, Vet_approved 137-58-6 3676
21
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
22
Vitamin D3 Approved, Nutraceutical 67-97-0 5280795 6221
23 abobotulinumtoxinA
24 Neurotransmitter Agents
25 Cholinergic Agents
26 Botulinum Toxins
27 Botulinum Toxins, Type A
28 Trace Elements
29 Nutrients
30 Vitamins
31 Micronutrients
32 Calciferol
33 Antibodies, Blocking

Interventional clinical trials:

(show top 50) (show all 77)
# Name Status NCT ID Phase Drugs
1 Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAX™ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children Completed NCT00313950 Phase 4
2 Immunogenicity and Safety of Concurrent Administration of Live, Attenuated SA 14-14-2 Japanese Encephalitis Vaccine and Measles-Mumps-Rubella Vaccine in Infants 9-12 Months of Age in the Philippines Completed NCT02880865 Phase 4
3 Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life Completed NCT00126997 Phase 4
4 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
5 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella), Single Dose and Multidose Presentations in Children 12 to 23 Months of Age. Completed NCT01777529 Phase 4
6 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines in Children Under 2 Years Old in Argentina Completed NCT03368495 Phase 4
7 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Completed NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
8 Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
9 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine Completed NCT02325310 Phase 4
10 Seroprevalence of Antibodies to Measles, Mumps, and Rubella, and Serologic Responses After Vaccination Among Human Immunodeficiency Virus (HIV)-1 Infected Adults in Northern Thailand Completed NCT02724852 Phase 4
11 Randomized, Double-blind, Controlled Phase Ⅳ Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine in Healthy Infants Aged 8 ~12 Months. Recruiting NCT04364399 Phase 4
12 Measles-mumps-rubella Vaccine at 6 Months of Age, Immunology, and Childhood Morbidity in a High-income Setting Recruiting NCT03780179 Phase 4
13 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Recruiting NCT04111432 Phase 4
14 A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of MMRV Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers Completed NCT00626327 Phase 3
15 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
16 A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP) Completed NCT01536405 Phase 3
17 Blinded, Randomised, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Combined Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children in Their Second Year of Life Completed NCT00127023 Phase 3
18 Safety and Immunogenicity Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine, in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
19 A Blind, Randomized and Controlled Clinical Trial With Live Attenuated Mumps Vaccines in Healthy Infants Completed NCT02692599 Phase 3
20 Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762) Completed NCT01621802 Phase 3
21 An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ProQuad® When Administered by Intramuscular (IM) Route or Subcutaneous (SC) Route to Healthy Children Aged 12 to 18 Months Completed NCT00402831 Phase 3
22 An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant Versus Separate Administration of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) and a Booster Dose of Infanrix® Hexa in Healthy Children 12 to 23 Months of Age Completed NCT00432042 Phase 3
23 An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT00109343 Phase 3
24 A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION) Completed NCT03620162 Phase 3
25 An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life Completed NCT00560755 Phase 3
26 An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA Administered to Healthy Children From 9 Months of Age Completed NCT00566527 Phase 3
27 A Phase III Open-label Randomised Study, to Evaluate the Immunogenicity and Safety of the Concomitant Administration of V419 (PR5I) Given at 2, 3 and 4 Months of Age With Two Types of Meningococcal Serogroup C Conjugate (MCC) Vaccines Given at 3 and 4 Months of Age, and Followed by the Administration at 12 Months of Age of a Combined Haemophilus Influenzae Type b-MCC Vaccine Completed NCT01553279 Phase 3
28 A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly With M-M-R™ II Completed NCT03239873 Phase 3
29 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Other Pediatric Vaccines in Healthy Toddlers Completed NCT03205371 Phase 3
30 A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Completed NCT00806195 Phase 3
31 A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II Completed NCT02062502 Phase 3
32 Follow-up to Evaluate the the Immunogenicity & Safety of GSK Biologicals' MMRV Vaccine Given as a Two-dose Schedule in the Second Year of Life, as Compared to Separate Administration of GSK Biologicals' Priorix® & Varilrix®. Completed NCT00406211 Phase 3
33 Blinded, Randomized Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children During the Second Year of Life Completed NCT00127010 Phase 3
34 A Phase IIIb, Open, Randomised, Multicentre, Primary Study in Healthy Children, to Establish the Non-inferiority of GlaxoSmithKline (GSK) Biologicals' MeMuRu-OKA Vaccine (Administered at 9 and 15 Months of Age) Versus Priorix™ (9 Months of Age) and Priorix™ Co-administered With Varilrix™ at 15 Months of Age (Comparator) and Also to Evaluate the Non-inferiority of Priorix™ (9 Months of Age) and MeMuRu-OKA Vaccine (15 Months of Age) Versus the Comparator, All Administered Subcutaneously as Two-dose Primary Vaccination Course Completed NCT00969436 Phase 3
35 A Comparison of the Safety, Tolerability, and Immunogenicity of a Refrigerator-Stable Measles, Mumps, Rubella, and Varicella Combination Vaccine V221 (Refrigerated) Versus V221 (Frozen) in Healthy Children Completed NCT00092430 Phase 3
36 A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age Completed NCT00092391 Phase 3
37 Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE CV) Concomitantly Administered With Measles, Mumps, and Rubella (MMR) Vaccine in Toddlers in Taiwan. Completed NCT01188343 Phase 3
38 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
39 Immunogenicity and Safety Study of GSK Biologicals' Priorix Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s Measles-mumps-rubella (MMR) Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life Completed NCT01681992 Phase 3
40 Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762) Completed NCT02058563 Phase 3
41 Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age Completed NCT00197015 Phase 3
42 Administration of Frozen Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine to Healthy Children at 4 to 6 Years of Age Completed NCT00985166 Phase 3
43 Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine Completed NCT00226499 Phase 3
44 Comparison of the Safety, Tolerability, and Immunogenicity of 3 Consistency Lots of Frozen Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) in Healthy Children Completed NCT00985153 Phase 3
45 A Randomized, Placebo-Controlled, Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, (MMRIIÒ) and Varicella (VARIVAXÒ) Vaccines Administered Concurrently to Healthy Children (AV018) Completed NCT00192491 Phase 3
46 A Pilot Study to Compare the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine and the Concomitant Administration of the Currently Licensed VARIVAX™ and M-M-R II™ in Healthy Children Completed NCT00975507 Phase 3
47 Immunogenicity and Safety Study of GlaxoSmithKline Biological's Live Attenuated Measles Mumps Rubella Varicella Vaccine (PriorixTetra™) When Co-administered With Conjugated Meningococcal C Vaccine (Meningitec®, Nuron Biotechs' Vaccine) in Healthy Children Completed NCT01506193 Phase 3
48 Consistency Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Healthy Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
49 Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11 Recruiting NCT04591405 Phase 2, Phase 3
50 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe Recruiting NCT03547271 Phase 3

Search NIH Clinical Center for Mumps

Cochrane evidence based reviews: mumps

Genetic Tests for Mumps

Anatomical Context for Mumps

MalaCards organs/tissues related to Mumps:

40
Skin, Salivary Gland, T Cells, Bone, Bone Marrow, Brain, Kidney

Publications for Mumps

Articles related to Mumps:

(show top 50) (show all 8316)
# Title Authors PMID Year
1
Mumps Cases Disproportionately Affecting Persons Living with HIV Infection and Men Who Have Sex with Men - Chicago, Illinois, 2018. 61 42
32673295 2020
2
Recurrent outbreaks of mumps in Lothian and the impact of waning immunity. 42 61
32616093 2020
3
Molecular epidemiology of mumps viruses in the Netherlands, 2017-2019. 42 61
32925979 2020
4
Antiviral responses of human Leydig cells to mumps virus infection or poly I:C stimulation. 54 61
18567898 2008
5
Composition and assembly of STAT-targeting ubiquitin ligase complexes: paramyxovirus V protein carboxyl terminus is an oligomerization domain. 54 61
16051811 2005
6
Suppression of thermotolerance in mumps virus-infected cells is caused by lack of HSP27 induction contributed by STAT-1. 61 54
12917439 2003
7
[The rapid detection kit based on neuraminidase activity of influenza virus]. 54 61
11225310 2000
8
Poor induction of interferon-induced 2',5'-oligoadenylate synthetase (2-5 AS) in cells persistently infected with mumps virus is caused by decrease of STAT-1 alpha. 61 54
9856085 1998
9
Investigation of IFN type-I receptor and IFN regulatory factor expression relating to induction of 2', 5'-oligoadenylate synthetase in cells persistently infected with the mumps virus. 61 54
8981353 1996
10
Immunization status and re-immunization of childhood acute lymphoblastic leukemia survivors. 61
32882157 2021
11
[Preliminary practice of multidisciplinary cooperative vaccination management model for pediatric patients with hematological and oncological diseases]. 61
33775050 2021
12
Non-linear relationships and interactions of meteorological factors on mumps in Jinan, China. 61
33180186 2021
13
Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction. 61
33770235 2021
14
Response to Letter to the Editor: Do age-related differences in the incidence of mumps deafness reflect a true difference or a misclassification of mumps deafness? 61
33746150 2021
15
Do age-related differences in the incidence of mumps deafness reflect a true difference or a misclassification of mumps deafness? 61
33746149 2021
16
Comparative study of intralesional tuberculin protein purified derivative (PPD) and intralesional measles, mumps, rubella (MMR) vaccine for multiple resistant warts. 61
33118675 2021
17
Intralesional injection of Candida albicans antigen versus measles, mumps, and rubella vaccine for treatment of plantar warts. 61
33765749 2021
18
Immunotherapy using topical measles, mumps and rubella vaccine for treatment of verruca plana. 61
33769758 2021
19
Cross-neutralization between vaccine and circulating wild-type mumps viruses in Korea. 61
33642163 2021
20
Impact of complement and difference of cell-based assay and ELISA in determination of neutralization capacity against mumps and measles virus. 61
33412172 2021
21
Anaesthesia mumps after laparoscopic right hemicolectomy under general anaesthesia: A case report. 61
33607364 2021
22
Vigilance regarding immune thrombocytopenic purpura after COVID-19 vaccine. 61
33788135 2021
23
Does prior immunization with measles, mumps, and rubella vaccines contribute to the antibody response to COVID-19 antigens? 61
33787513 2021
24
Thirty-six COVID-19 cases preventively vaccinated with mumps-measles-rubella vaccine: All mild course. 61
32894782 2021
25
Serum Concentration of Antibodies to Mumps, but Not Measles, Rubella, or Varicella, Is Associated with Intake of Dietary Fiber in the NHANES, 1999-2004. 61
33801237 2021
26
[Mumps: Parotid swelling and skin rash in a patient vaccinated with the Rubini strain]. 61
32505506 2021
27
Vaccine hesitancy and reported non-vaccination in an Irish pediatric outpatient population. 61
33774718 2021
28
Gelatin-Containing Vaccines for Varicella, Zoster, Measles, Mumps, and Rubella Induce Basophil Activation in Patients with Alpha-Gal Syndrome. 61
33735861 2021
29
CMUT-Based Sensor for Acoustic Emission Application: Experimental and Theoretical Contributions to Sensitivity Optimization. 61
33799399 2021
30
Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran. 61
33765968 2021
31
Isatis indigotica: a review of phytochemistry, pharmacological activities and clinical applications. 61
33779758 2021
32
[2nd Seroprevalence Study in Spain, 2017-2018.] 61
33734212 2021
33
Vaccine coverage among children with epilepsy in two Canadian provinces: A Canadian immunization research network study. 61
33722410 2021
34
Liu Shen Wan inhibits influenza virus-induced secondary Staphylococcus aureus infection in vivo and in vitro. 61
33766755 2021
35
Trends in voluntary vaccination coverage in a Japanese city. 61
33780596 2021
36
Impact of social distancing on incidence of vaccine-preventable diseases, South Korea. 61
33079384 2021
37
Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants. 61
33736915 2021
38
Hyperbaric Oxygen Therapy for Mumps-Associated Outer Retinitis with Frosted Branch Angiitis. 61
33545017 2021
39
Immunity and Vaccination Against Measles, Mumps, and Rubella in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients. 61
33775586 2021
40
Health Maintenance for Women of Reproductive Age. 61
33587575 2021
41
Seroprevalence of vaccine-preventable and non-vaccine preventable infections in migrants in Spain. 61
33611577 2021
42
A Study of Varicella Seroprevalence in a Pediatric and Adolescent Population in Florence (Italy). Natural Infection and Vaccination-Acquired Immunization. 61
33672915 2021
43
A longitudinal cohort study of childhood MMR vaccination and seizure disorder among American children. 61
32981784 2021
44
Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020. 61
33478793 2021
45
Immunodeficiency in a patient with microcephalic osteodysplastic primordial dwarfism type I as compared to Roifman syndrome. 61
33059947 2021
46
Is it time to reconsider measles, mumps, and rubella immunisation strategies? 61
32888411 2021
47
Intralesional Measles, Mumps, and Rubella Vaccine Versus Intralesional Candida Antigen in the Treatment of Common and Plantar Warts. 61
33533654 2021
48
Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants. 61
33609034 2021
49
Maternal vaccines-safety in pregnancy. 61
33773923 2021
50
Post Vaccine Rubella During a Measles Outbreak: Clinical Case. 61
31851892 2021

Variations for Mumps

Expression for Mumps

Search GEO for disease gene expression data for Mumps.

Pathways for Mumps

Pathways related to Mumps according to GeneCards Suite gene sharing:

(show top 50) (show all 108)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
2
Show member pathways
13.96 TNFRSF1A TNF TLR3 STAT2 STAT1 IRAK1
3
Show member pathways
13.94 TNFRSF1A TNF STAT2 STAT1 RIPK1 IRAK1
4
Show member pathways
13.8 TNFRSF1A TNF IL6 IL2 IL1B IL10
5
Show member pathways
13.67 TNFRSF1A TNF STAT2 STAT1 RIPK1 IRF1
6
Show member pathways
13.57 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
7
Show member pathways
13.38 TNFRSF1A TNF TLR3 STAT2 STAT1 IRAK1
8
Show member pathways
13.16 TNFRSF1A TNF TLR3 STAT2 STAT1 IRF1
9
Show member pathways
13.05 TNF STAT1 IL6 IL2 IL1B IL10
10
Show member pathways
13.05 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
11 13.01 STAT2 STAT1 IL6 IL2 IFNG IFNAR2
12
Show member pathways
12.98 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
13
Show member pathways
12.97 TNFRSF1A TNF STAT2 STAT1 IRF1 IRAK1
14
Show member pathways
12.92 TNFRSF1A TNF TLR3 RIPK1 IRAK1 IL6
15
Show member pathways
12.92 TNF TLR3 STAT1 RIPK1 IRF1 IRAK1
16
Show member pathways
12.88 TNFRSF1A TNF RIPK1 IRAK1 IL6 IL1B
17
Show member pathways
12.86 TNFRSF1A TNF STAT1 IL6 IL2
18
Show member pathways
12.84 TNFRSF1A TNF STAT1 RIPK1 IL1B IFNG
19
Show member pathways
12.82 TNFRSF1A TNF IL2 IL10 IFNG IFNAR2
20
Show member pathways
12.81 TNF STAT1 IL6 IL2 IL1B IL10
21
Show member pathways
12.81 TNF STAT1 RIPK1 IL6 IL2 IL1B
22
Show member pathways
12.8 TNFRSF1A TNF RIPK1 IRF1 IRAK1
23 12.8 TNFRSF1A TNF TLR3 STAT2 STAT1 IRAK1
24
Show member pathways
12.78 TNF STAT1 IL6 IL2 IL1B IL10
25
Show member pathways
12.76 STAT2 STAT1 IRF1 IFNG IFNB1 IFNAR2
26
Show member pathways
12.75 TNFRSF1A TNF TLR3 RIPK1 IRAK1 IL1B
27
Show member pathways
12.74 TLR3 RIPK1 IRAK1 IL6 IL1B IFNB1
28
Show member pathways
12.72 TNF RIPK1 IRF1 IFNG IFNB1 IFNA1
29
Show member pathways
12.69 TNF IL2 IFNG IFNB1 IFNAR2 IFNA1
30 12.68 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
31
Show member pathways
12.63 STAT2 STAT1 IL6 IL2 IL10 IFNG
32 12.55 TNFRSF1A TNF RIPK1 IL1B IFNB1
33
Show member pathways
12.55 TNF TLR3 STAT1 IRF1 IRAK1 IL6
34
Show member pathways
12.5 TNFRSF1A TNF STAT1 IRAK1 IL1B IL10
35 12.49 TNFRSF1A TNF IL6 IL2 HLA-DPB1
36
Show member pathways
12.48 TNFRSF1A TNF IL6 IL2 IL10
37
Show member pathways
12.48 TNF IL6 IL2 IL1B IFNG
38
Show member pathways
12.46 TNF TLR3 RIPK1 IRAK1 IL6 IFNB1
39
Show member pathways
12.45 TNF STAT2 STAT1 IRF1 IL6 IL2
40 12.45 TNF STAT2 STAT1 RIPK1 IL6 IL1B
41 12.45 TNFRSF1A TNF STAT1 IRAK1 IL6 IL1B
42
Show member pathways
12.44 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
43
Show member pathways
12.42 TNF IL6 IL1B IFNG
44
Show member pathways
12.42 TNFRSF1A TNF STAT1 RIPK1
45
Show member pathways
12.42 TNF STAT1 IRF1 IRAK1 IL6 IL1B
46
Show member pathways
12.39 TNF STAT2 STAT1 IRF1 IL6 IL2
47 12.38 TNFRSF1A TNF TLR3 STAT1 IL6 IFNG
48 12.32 TNF IRAK1 IL6 IL2 IL1B IL10
49 12.28 TNF IL6 IL1B IL10
50 12.28 TNFRSF1A TNF STAT2 STAT1 IL1B IFNG

GO Terms for Mumps

Cellular components related to Mumps according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNFRSF1A TNF IL6 IL2 IL1B IL10
2 extracellular space GO:0005615 9.36 TNFRSF1A TNF TLR3 IL6 IL2 IL1B

Biological processes related to Mumps according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.4 TNFRSF1A TLR3 STAT2 STAT1 RIPK1 IRAK1
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.28 TNFRSF1A TNF TLR3 STAT1 RIPK1 IRF1
3 immune system process GO:0002376 10.25 TLR3 IRF1 IRAK1 IL2 HLA-DPB1 EIF2AK2
4 positive regulation of transcription, DNA-templated GO:0045893 10.22 TNF STAT1 IRF1 IL6 IL1B IL10
5 negative regulation of apoptotic process GO:0043066 10.2 RIPK1 IRAK1 IL6 IL2 IL10 EIF2AK2
6 positive regulation of gene expression GO:0010628 10.19 TNF TLR3 IL6 IL1B IFNG CD46
7 viral process GO:0016032 10.19 TNFRSF1A STAT2 STAT1 RIPK1 IRAK1 EIF2AK2
8 adaptive immune response GO:0002250 10.18 IL2 IFNG IFNB1 IFNA1 HLA-DPB1 CD46
9 inflammatory response GO:0006954 10.16 TNFRSF1A TNF TLR3 RIPK1 IL6 IL1B
10 immune response GO:0006955 10.16 TNF TLR3 IL6 IL2 IL1B IL10
11 negative regulation of cell proliferation GO:0008285 10.15 IRF1 IL6 IL1B IL10 EIF2AK2
12 positive regulation of protein phosphorylation GO:0001934 10.08 TNF RIPK1 IL2 IL1B IFNG
13 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.06 TNFRSF1A TNF TLR3 RIPK1 IRAK1
14 cellular response to lipopolysaccharide GO:0071222 10.04 TNF IRAK1 IL6 IL1B IL10
15 tumor necrosis factor-mediated signaling pathway GO:0033209 10.02 TNFRSF1A TNF STAT1 RIPK1
16 positive regulation of DNA-binding transcription factor activity GO:0051091 10.01 TNF IL6 IL1B IL10
17 positive regulation of tumor necrosis factor production GO:0032760 10 TLR3 RIPK1 IL6 IFNG
18 positive regulation of JNK cascade GO:0046330 9.99 TNF TLR3 RIPK1 IL1B
19 cellular response to mechanical stimulus GO:0071260 9.99 TNFRSF1A TLR3 IRF1 IL1B
20 positive regulation of interleukin-6 production GO:0032755 9.99 TNF TLR3 IL6 IL1B IFNG
21 regulation of insulin secretion GO:0050796 9.97 TNF IL6 IL1B IFNG
22 interferon-gamma-mediated signaling pathway GO:0060333 9.97 STAT1 IRF1 IFNG HLA-DPB1
23 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.97 TNFRSF1A TNF IL6 IL2 IFNG
24 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.95 TNFRSF1A TNF TLR3 RIPK1
25 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.95 TNF TLR3 IRAK1 IL1B EIF2AK2
26 positive regulation of smooth muscle cell proliferation GO:0048661 9.94 TNF STAT1 IRAK1 IL6
27 B cell differentiation GO:0030183 9.93 IL10 IFNB1 IFNA1
28 apoptotic signaling pathway GO:0097190 9.93 TNF TLR3 RIPK1
29 cellular response to organic cyclic compound GO:0071407 9.93 TNF STAT1 IL1B
30 response to glucocorticoid GO:0051384 9.92 TNF IL6 IL10
31 positive regulation of interleukin-1 beta production GO:0032731 9.92 TNF IL6 IFNG
32 positive regulation of type I interferon production GO:0032481 9.92 TLR3 IRF1 IRAK1
33 extrinsic apoptotic signaling pathway GO:0097191 9.92 TNF TLR3 RIPK1 IFNG
34 positive regulation of interferon-gamma production GO:0032729 9.92 TNF TLR3 IL2 IL1B HLA-DPB1
35 positive regulation of phagocytosis GO:0050766 9.91 TNF IL1B IFNG
36 positive regulation of nitric oxide biosynthetic process GO:0045429 9.91 TNF IL1B IFNG
37 negative regulation of viral genome replication GO:0045071 9.91 TNF IFNB1 EIF2AK2
38 positive regulation of interleukin-12 production GO:0032735 9.91 TLR3 IRF1 IFNG
39 response to exogenous dsRNA GO:0043330 9.91 TLR3 IFNB1 IFNA1
40 positive regulation of T cell proliferation GO:0042102 9.91 IL6 IL2 IL1B HLA-DPB1 CD46
41 response to virus GO:0009615 9.91 TNF TLR3 IFNG IFNB1 IFNAR2 EIF2AK2
42 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 TNF TLR3 RIPK1 IRAK1 IL6 IL1B
43 B cell proliferation GO:0042100 9.9 IL10 IFNB1 IFNA1
44 positive regulation of JAK-STAT cascade GO:0046427 9.9 TNF IL6 IL10
45 lipopolysaccharide-mediated signaling pathway GO:0031663 9.9 TNF IRAK1 IL1B
46 JAK-STAT cascade GO:0007259 9.9 STAT2 STAT1 IFNG IFNAR2
47 microglial cell activation GO:0001774 9.89 TNF TLR3 IFNG
48 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.89 TNFRSF1A TNF RIPK1
49 positive regulation of interleukin-8 production GO:0032757 9.89 TNF TLR3 RIPK1 IL6 IL1B
50 negative regulation of neurogenesis GO:0050768 9.88 TNF IL6 IL1B

Molecular functions related to Mumps according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.16 UBQLN4 TNFRSF1A TNF TLR3 STAT2 STAT1
2 identical protein binding GO:0042802 9.61 UBQLN4 TNFRSF1A TNF TLR3 STAT2 STAT1
3 cytokine activity GO:0005125 9.23 TNF IL6 IL2 IL1B IL10 IFNG

Sources for Mumps

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....